{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANOVA of van der Waerden scores","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.55770","value":"0.1250"},{"groupId":"OG001","spread":"0.57706","value":"0.5000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"395"}],"units":"Participants"}],"description":"The HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). HAQscore on a scale ranges from 0 (no disability) to 3 (completely disabled). Higher scores indicate worsening.","dispersionType":"Standard Deviation","groups":[{"description":"Participants randomized to receive their stable dose of commercial MTX (between 15-25 mg/week) and placebo IV infusions at Weeks 0, 4, 12, 16, and 20. Participants will be crossed over to Golimumab 2 mg/kg at Week 24, and receive administrations at Weeks 24, 28 and q8 weeks thereafter up to Week 100. Subjects randomized to Group I (Placebo + MTX) will have the opportunity to enter early escape at Week 16 and initiate Golimumab 2 mg/kg infusions (Weeks 16, 20, and q8 weeks up to Week 100) if they demonstrate a \\< 10% improvement in both tender and swollen joint count.","id":"OG000","title":"Group I: Placebo + Methotrexate (MTX)"},{"description":"Participants randomized to receive 2 mg/kg of Golimumab intravenously at Weeks 0, 4, and q8 weeks up to Week 100. Participants will be maintained on their stable dose of commercial MTX (between 15 and 25 mg/week) throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.","id":"OG001","title":"Group II: Golimumab 2 mg/kg + Methotrexate (MTX)"}],"paramType":"MEAN","populationDescription":"Intent-to-treat: all patients analyzed according to the treatment for which they were randomized.","reportingStatus":"POSTED","timeFrame":"Week 14","title":"Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}